- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Wearables in Pharma & Biotech Market by Product (Smartwatches, CGMs, Bands, Rings, Patches, Injectors), Therapy (Diabetes, Cardio, Onco, Mental Health), Application (Drug Discovery, Clinical Trials, Medication Adherence), End User - Global Forecasts to 2031
USD 9.97 BN
MARKET SIZE, 2031
CAGR 20.2%
(2026-2031)
457
REPORT PAGES
531
MARKET TABLES
WEARABLES IN PHARMA & BIOTECH MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global wearables in pharma & biotech market is projected to grow from USD 3.98 billion in 2026 to USD 9.97 billion by 2031, at a CAGR of 20.2% during the forecast period. The market was valued at USD 3.35 billion in 2025. The market is driven by the increasing adoption of wearable devices in patient monitoring, clinical trials, and the development of real-world evidence in the pharmaceutical and biotech industries. Improvements in biosensors, AI-based analytics, and cloud-based data integration are also expected to increase the accuracy of the data generated. Furthermore, the move toward decentralized trials, as well as encouragement from the US Food and Drug Administration and the Centers for Medicare and Medicaid Services, is also expected to increase the adoption of wearable devices in the healthcare and life science sectors.
KEY TAKEAWAYS
-
By Region
North America accounted for the largest share (42.3%) of the global wearables in pharma & biotech market in 2025.
-
By Products
In 2025, the continuous glucose monitor (CGM) segment accounted for 31.3% of the wearables in pharma & biotech market.
-
By Therapeutic Area
The mental and behavioural health segment is projected to register the highest CAGR during the forecast period.
-
By Application
The clinical trials segment is projected to exhibit the fastest growth during the forecast period.
-
By End User
Pharmaceutical & biotech companies accounted for the largest share (53.5%) of the wearables in pharma & biotech market in 2025.
-
Competitive Landscape
Abbott, Dexcom Inc., and Masimo were identified as star players in the wearables in pharma & biotech market (global), given their strong market share and product footprint.
-
Competitive Landscape
Sibel Health Inc. has distinguished itself among startups and SMEs by securing strong footholds in specialized niche areas, underscoring its potential as an emerging market leader.
The wearables in pharma & biotech market is driven by factors such as an increase in the use of continuous monitoring devices in clinical trials and managing chronic conditions, an increase in the adoption of digital biomarkers, and a rise in the adoption of decentralized and remote patient-centric care models. However, factors like data privacy issues, lack of standardization in endpoints measured by wearables, and issues related to data accuracy and patient compliance are restraining the growth of this market.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The wearables in pharma & biotech market is changing significantly due to the rise in decentralized clinical trials, the increase in demand for real-world evidence, and developments related to biosensors, AI, and digital health technologies. Pharmaceutical companies and research organizations are increasingly using wearables for continuous remote patient monitoring and high-frequency data collection. Developments in multi-parameter biosensors, smart patches, and connected wearables are helping enhance the quality of data collected, whereas the development and use of consumer-grade wearables are enhancing scalability and cost efficiency. On the other hand, the integration with cloud technologies, AI, and digital biomarkers is helping to enhance the quality of decision-making in drug development. However, changing regulatory requirements, data privacy issues, and the need to validate digital endpoints are affecting vendor strategy and investment decisions, resulting in a shift toward an integrated, secure, and outcome-driven digital health ecosystem.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
-
Shift toward value-based and patient-centric healthcare models
-
Rising prevalence of chronic diseases requiring continuous patient monitoring
RESTRAINTS
Impact
Level
-
High implementation and integration costs for healthcare providers
-
Data privacy and cybersecurity concerns
OPPORTUNITIES
Impact
Level
-
Expansion of remote patient monitoring and home-based care models
-
Integration of advanced analytics and personalized healthcare
CHALLENGES
Impact
Level
-
Interoperability limitations with existing healthcare IT systems
-
Low patient adoption and digital literacy barriers
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The market for wearables in pharma & biotech is fueled by the move toward value-based and patient-centric care, where outcomes and cost efficiency are prioritized. Wearable technologies allow for real-time monitoring of patients, thus providing a personalized care experience. These technologies can generate real-world evidence and improve decision-making in healthcare. They are more aligned with value-based care, where outcomes are prioritized. Wearables can also minimize hospitalizations and provide a remote care experience, thus fueling the market in the pharma and healthcare ecosystem.
The market growth is restrained by cost factors related to wearable device deployment, the setting up of associated infrastructure, and integrating existing healthcare information technology solutions. Healthcare organizations need to invest in compatible software solutions, data management solutions, cybersecurity solutions, and training programs. Moreover, wearable device data integration with electronic health records is also a challenge. Small healthcare organizations might find it difficult to afford such solutions.
The prospect of remote patient monitoring and home-based care is a big opportunity for wearable technologies. This is because wearable technologies allow for constant monitoring of vital signs and health parameters outside the hospital setting. This home-based care is being driven by the need for convenience, the aging population, and the management of chronic diseases. This presents a significant growth opportunity for wearable technologies.
One of the major issues in the wearables market is the lack of interoperability between existing healthcare IT systems and wearable devices. This is primarily because of the differences in data formats and the lack of standardized protocols. This poses a significant challenge in effectively utilizing data generated by wearable devices, impacting the complexity of integration processes in the healthcare and pharmaceutical industries.
WEARABLES IN PHARMA & BIOTECH MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Integration of wearables in clinical trials for continuous monitoring of physiological parameters | Improves endpoint accuracy, reduces site visits, enables decentralized trials |
|
|
Continuous glucose monitoring for diabetes management and research | Provides real-time glucose data, improves glycemic control, supports clinical studies |
|
|
Deployment of CGMs for remote monitoring and therapeutic evaluation | Enables continuous monitoring, reduces invasive testing, supports long-term disease management |
|
|
Continuous monitoring of oxygen saturation and vital signs via wearables | Improves patient safety, enables early intervention |
|
|
Use of wearable-enabled platforms for real-world data collection in drug development | Enhances real-world evidence generation and patient-centric trial design |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The wearables in pharma & biotech market ecosystem comprises top device manufacturers such as Abbott Laboratories, Dexcom Inc., Medtronic, and Masimo Corporation, along with innovative players such as Sibel Health, Byteflies, Strados Labs, and Onera Health, among others. These players contribute to the advancement of highly sophisticated biosensors and wearable devices. They are further enabled with clinical data and connected health players such as GE Healthcare, Koninklijke Philips N.V., and F. Hoffmann-La Roche Ltd. These organizations help in enabling data integration and analytics. Additionally, regulatory organizations such as the FDA and EMA help in ensuring compliance and validation. Pharmaceutical and healthcare organizations, along with research organizations, help in ensuring the adoption of wearables in various activities, such as clinical trials and real-world evidence.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The product segment of the wearables in pharma and biotech market is driven by the increasing popularity of Continuous Glucose Monitors (CGMs), which hold the largest market share due to their high utility in disease management. Pharmaceutical companies, healthcare providers, and patients are increasingly adopting the technology to manage diseases in a continuous manner. The technology provides a real-time view of the health of patients, allowing them to manage the disease more effectively. Unlike other wearable devices in the market, CGMs involve the repeated replacement of the sensors, thereby increasing the demand for the product in the market.
The diabetes segment leads the wearables in pharma and biotech market due to the high prevalence of the disease worldwide and the need for constant monitoring and management of the disease. Wearable technologies, such as continuous glucose monitors, have become popular tools in the management of diabetes as they constantly monitor the levels of glucose in the body, thus helping manage the disease and prevent the occurrence of related health risks. The chronic nature of the disease has made it essential to monitor and manage the health of diabetic patients, making wearable technology a crucial tool in the management of the disease.
The clinical trials segment holds the largest share in the wearables in pharma and biotech market, due to the growing trend of wearables for the continuous monitoring of patients and the collection of data and information in real-time. Wearable technologies, such as biosensors and mobile-connected monitoring devices, are useful in accurately tracking and monitoring the vital signs and activity levels of patients. Wearable devices are also valuable for collecting information and data accurately and efficiently by eliminating the need for patients to visit the hospital repeatedly and manually input data. Additionally, integrating the information and data obtained through devices, electronic data capture systems, telemedicine technologies, and AI-based analytics makes these devices a vital part of clinical trials in the most efficient and effective way.
By end user, the pharma & biotech companies segment leads the wearables in pharma & biotech market, due to the increased dependency on wearable technologies in drug development, clinical trials, and real-world evidence. These companies are increasingly relying on wearable technologies to monitor patient information, thus enhancing the overall efficacy, safety, and adherence of a drug in clinical trial environments. Wearable technologies help pharma and biotech companies conduct more cost-effective and faster clinical trials, expanding their patient base. They are also useful in analyzing patient information, which enhances personalized medicine. Increasingly, wearable technologies are used in drug development, boosting patient-centric approaches, digital therapeutics, and personalized medicine, thereby making pharma and biotech companies the leading end-user segment in the market.
REGION
Asia Pacific to to be fastest-growing region in global wearables in pharma & biotech market during forecast period
The Asia Pacific region is likely to experience the fastest growth in the wearables in pharma & biotech market over the forecast period, owing to the rising healthcare expenditure and the prevalence of chronic conditions in the region. Additionally, the region is witnessing favorable government initiatives and the adoption of decentralized clinical trials. The popularity of wearable devices is growing in the region due to partnerships between local healthcare providers and international wearable manufacturers. In the region, countries such as China and India have large and aging populations. Moreover, the rising awareness of preventive care and the growing focus on personalized medicine are driving the market for wearable devices in the region.
WEARABLES IN PHARMA & BIOTECH MARKET: COMPANY EVALUATION MATRIX
Masimo (Star Player) is a major player in this market because of its wide range of non-invasive monitoring solutions. Their focus on continuous patient monitoring and analysis is a benchmark for innovation and quality in this segment. GE Healthcare (Emerging Leader) is an emerging company with significant experience in the medical devices and digital health segment. GE Healthcare is aiming to make a mark in this segment by providing connected monitoring solutions and analysis of information using technology. Masimo is a major player in this segment and has already made a mark with its product portfolio and trial experience. However, it faces competition from emerging companies like GE Healthcare that are innovating at a rapid rate in the wearable technology segment.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- BD (US)
- Abbott (US)
- Masimo (US)
- Apple Inc. (US)
- Dexcom, Inc. (US)
- Medtronic (Ireland)
- iRhythm Technologies, Inc. (US)
- BioIntelliSense, Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Koninklijke Philips N.V. (Netherlands)
- GE HealthCare (US)
- Biobeat Technologies Ltd. (Israel)
- Empatica Inc. (US)
- VitalConnect, Inc. (US)
- Ametris, LLC (US)
- AliveCor, Inc. (US)
- Boston Scientific Corporation (US)
- Withings SA (France)
- VivaLNK, Inc. (US)
- MediBioSense Ltd. (Switzerland)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) (Base Year) | USD 3.35 Billion |
| Market Size in 2026 (Value) (Estimated Year) | USD 3.98 Billion |
| Market Forecast in 2031 (Value) (Forecast Year) | USD 9.97 Billion |
| CAGR | 20.2% |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | USD Billion |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, the Middle East & Africa, Latin America |
WHAT IS IN IT FOR YOU: WEARABLES IN PHARMA & BIOTECH MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Competitive Landscape Mapping | Profiles, product portfolios, and market share of leading wearable technology vendors for pharma and biotech, covering continuous glucose monitors, cardiac and respiratory monitors, biosensors, digital therapeutics platforms, and AI-enabled analytics solutions. | Enables benchmarking of wearable offerings, identifies differentiation opportunities in device capabilities, data integration, and analytics, supports portfolio optimization, and aids in strategic partnerships, licensing, and M&A planning. |
| Market Entry & Growth Strategy | Regional assessment of wearable adoption trends, chronic disease prevalence, regulatory frameworks, reimbursement policies, and clinical trial integration across pharma, biotech, and research organizations. | Reduces go-to-market risk, accelerates adoption through informed localization and compliance strategies, and supports market expansion into emerging healthcare ecosystems. |
| Regulatory & Operational Risk Analysis | Evaluation of compliance with FDA, CE, ISO, HIPAA, GDPR, and other local medical device and data protection regulations; analysis of interoperability standards (HL7, FHIR) and data security challenges in remote monitoring and clinical trial use. | Supports regulatory readiness and risk mitigation, enhances device and data governance credibility, and ensures vendor alignment with patient safety, privacy, and clinical trial standards. |
| Technology Adoption Trends | Insights into adoption of AI- and ML-enabled wearable analytics, integration with EHRs, clinical trial platforms, population health systems, and personalized medicine programs. | Guides R&D prioritization, informs investment in connected health and digital therapeutics, and supports pharma and biotech companies in aligning wearable solutions with clinical outcomes, patient adherence, and real-world evidence generation. |
RECENT DEVELOPMENTS
- January 2026 : LabCorp announced a collaboration with Roche to adopt FDA-cleared digital pathology slide scanners, advancing digital pathology workflows that improve diagnostic efficiency, accuracy, and AI integration across LabCorp’s laboratory services.
- August 2025 : Abbott released the latest version of the FreeStyle Libre 2 Plus sensor, which offers automatic glucose level readings in one-minute intervals and provides optional real-time alerts for high or low levels of glucose in the blood. This sensor offers the option of continuous metabolic monitoring through smartphone connectivity and can be utilized for improved management of diabetes and the integration of health data with the therapeutic and research process.
- August 2024 : Masimo achieved FDA 510(k) clearance for connectivity between Masimo's W1 Medical Watch and Masimo SafetyNet telemonitoring system. The connectivity enables secure wrist-worn continuous measurement of oxygen saturation and pulse rate to be wirelessly sent through mobile apps and clinician portals, thus enabling remote patient monitoring, sharing of digital health information, and better clinical monitoring in both home and hospital settings.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
15
2
EXECUTIVE SUMMARY
3
PREMIUM INSIGHTS
4
MARKET OVERVIEW
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
SHIFT TOWARD VALUE-BASED AND PATIENT-CENTRIC HEALTHCARE MODELS
4.2.1.2
RISING PREVALENCE OF CHRONIC DISEASES REQUIRING CONTINUOUS PATIENT MONITORING
4.2.1.3
RAPID DIGITALIZATION OF HEALTHCARE AND EXPANSION OF TELEHEALTH SERVICES
4.2.2
RESTRAINTS
4.2.2.1
HIGH IMPLEMENTATION AND INTEGRATION COSTS FOR HEALTHCARE PROVIDERS
4.2.2.2
DATA PRIVACY AND CYBERSECURITY CONCERNS
4.2.3
OPPORTUNITIES
4.2.3.1
EXPANSION OF REMOTE PATIENT MONITORING AND HOME-BASED CARE MODELS
4.2.3.2
INTEGRATION OF ADVANCED ANALYTICS AND PERSONALIZED HEALTHCARE
4.2.4
CHALLENGES
4.2.4.1
INTEROPERABILITY LIMITATIONS WITH EXISTING HEALTHCARE IT SYSTEMS
4.2.4.2
LOW PATIENT ADOPTION AND DIGITAL LITERACY BARRIERS
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMICS INDICATORS
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.5
PRICING ANALYSIS
5.5.1
INDICATIVE PRICE FOR WEARABLES IN PHARMA & BIOTECH,
BY KEY PLAYERS (2025)
5.5.2
INDICATIVE PRICE FOR WEARABLES IN PHARMA & BIOTECH,
BY REGION (2025)
5.6
TRADE ANALYSIS
5.5.1
IMPORT SCENARIO (HS CODE 9018 )
5.5.2
EXPORT SCENARIO (HS CODE 9018)
5.6
KEY CONFERENCES AND EVENTS, 2026–2027
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8
INVESTMENT AND FUNDING SCENARIO
5.9
CASE STUDY ANALYSIS
5.10
IMPACT OF 2025 US TARIFF – WEARABLES IN PHARMA & BIOTECH MARKET
5.10.1
INTRODUCTION
5.10.2
KEY TARIFF RATES
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRIES/REGIONS
5.10.4.1
US
5.10.4.2
EUROPE
5.10.4.3
ASIA PACIFIC
5.10.5
IMPACT ON END-USE INDUSTRIES
5.11
CLINICAL TRIAL ANALYSIS
5.11.1
VOLUME OF CLINICAL TRIALS (PHASE III & IV)
5.11.1.1
ONCOLOGY
5.11.1.2
CARDIOVASCULAR
5.11.2
ADOPTION OF WEARABLES (%)
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
ADJACENT TECHNOLOGIES
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.5
PATENT ANALYSIS
6.6
FUTURE APPLICATIONS
6.7
IMPACT OF AI/GEN AI ON WEARABLES IN PHARMA & BIOTECH MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN WEARABLES IN PHARMA & BIOTECH
6.7.3
CASE STUDIES OF AI IMPLEMENTATION IN WEARABLES IN PHARMA & BIOTECH MARKET
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MARKET
7
REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
8.5
MARKET PROFITABILITY
9
WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT (MARKET SIZE & FORECAST TO 2031)
9.1
INTRODUCTION
9.2
SMARTWATCHES
9.3
FITNESS BANDS
9.4
SMART RINGS
9.5
CONTINUOUS GLUCOSE MONITORS (CGM)
9.6
PATCHES
9.7
WEARABLE INJECTORS
9.8
OTHERS
10
WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA (MARKET SIZE & FORECAST TO 2031)
10.1
INTRODUCTION
10.2
CARDIOVASCULAR
10.2.1
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) / SECONDARY PREVENTION
10.2.2
HEART FAILURE (HFREF AND HFPEF)
10.2.3
HYPERTENSION
10.2.4
ATRIAL FIBRILLATION (AF) / STROKE PREVENTION
10.2.5
PULMONARY HYPERTENSION
10.2.6
STRUCTURAL HEART DISEASE / INTERVENTIONAL CARDIOLOGY
10.3
ONCOLOGY
10.3.1
SOLID TUMORS
10.3.1.1
BREAST CANCER
10.3.1.2
LUNG CANCER
10.3.1.3
PROSTATE CANCER
10.3.1.4
COLORECTAL CANCER
10.3.1.5
BRAIN TUMOR
10.3.1.6
OTHER SOLID TUMORS
10.3.2
HEMATOLOGIC MALIGNANCIES
10.3.2.1
LEUKEMIA
10.3.2.2
LYMPHOMA
10.3.2.3
MULTIPLE MYELOMA
10.3.2.4
OTHER HEMATOLOGIC MALIGNANCIES
10.4
DIABETES
10.5
MENTAL HEALTH & BEHAVIORAL HEALTH
10.6
RESPIRATORY DISORDERS
10.7
LIFESTYLE & WELLNESS IMPROVEMENT
10.8
NEUROLOGY
10.9
MUSCULOSKELETAL DISORDERS / PAIN MANAGEMENT
10.10
WOMEN’S HEALTH & REPRODUCTIVE HEALTH
10.11
OTHER DISEASES
11
WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031)
11.1
INTRODUCTION
11.2
DRUG DISCOVERY
11.3
CLINICAL TRIALS
11.3.1
PHASE II
11.3.2
PHASE III
11.3.3
PHASE IV
11.4
MEDICATION ADHERENCE & BEHAVIORAL SUPPORT
11.5
CHRONIC DISEASE MONITORING
11.6
PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS
12
WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031)
12.1
INTRODUCTION
12.2
PHARMACEUTICAL & BIOTECH COMPANIES
12.3
HEALTHCARE PROVIDERS & CLINICIANS
12.4
OTHER END USERS
13
WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION (MARKET SIZE & FORECAST TO 2031)
13.1
INTRODUCTION
13.2
NORTH AMERICA
13.2.1
US
13.2.2
CANADA
13.3
EUROPE
13.3.1
GERMANY
13.3.2
FRANCE
13.3.3
UK
13.3.4
ITALY
13.3.5
SPAIN
13.3.6
REST OF EUROPE
13.4
ASIA PACIFIC
13.4.1
CHINA
13.4.2
JAPAN
13.4.3
INDIA
13.4.4
AUSTRALIA
13.4.5
SOUTH KOREA
13.4.6
REST OF ASIA PACIFIC
13.5
LATIN AMERICA
13.5.1
BRAZIL
13.5.2
MEXICO
13.5.3
REST OF LATIN AMERICA
13.6
MIDDLE EAST & AFRICA
13.6.1
GCC COUNTRIES
13.6.1.1
SAUDI ARABIA
13.6.1.2
UAE
13.6.1.3
REST OF GCC
13.6.2
SOUTH AFRICA
13.6.3
REST OF MIDDLE EAST & AFRICA
14
COMPETITIVE LANDSCAPE
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
14.1
OVERVIEW
14.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
14.3
REVENUE ANALYSIS, 2022–2025
14.4
MARKET SHARE ANALYSIS,
14.5
BRAND/SOFTWARE COMPARATIVE ANALYSIS
14.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
14.6.1
STARS
14.6.2
EMERGING LEADERS
14.6.3
PERVASIVE PLAYERS
14.6.4
PARTICIPANTS
14.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
14.6.5.1
COMPANY FOOTPRINT
14.6.5.2
REGION FOOTPRINT
14.6.5.3
PRODUCT FOOTPRINT
14.6.5.4
THERAPEUTIC AREA FOOTPRINT
14.6.5.5
APPLICATION FOOTPRINT
14.6.5.6
END USER FOOTPRINT
14.7
COMPANY EVAULATION MATRIX: STARTUPS/SMES,
14.7.1
PROGRESSIVE COMPANIES
14.7.2
DYNAMIC COMPANIES
14.7.3
RESPONSIVE COMPANIES
14.7.4
STARTING BLOCKS
14.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
14.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
14.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
14.8
COMPANY VALUATION AND FINANCIAL METRICS
14.9
COMPETITIVE SCENARIOS
14.9.1
PRODUCT LAUNCHES & UPGRADES
14.9.2
DEALS
14.9.3
EXPANSIONS
14.9.4
OTHER DEVELOPMENTS
15
COMPANY PROFILES
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, SERVICES, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE WEARABLES IN PHARMA & BIOTECH MARKET LANDSCAPE
15.1
KEY PLAYERS
15.1.1
BD
15.1.1.1
BUSINESS OVERVIEW
15.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
15.1.1.3
MNM VIEW
15.1.1.3.1
KEY STRENGTHS
15.1.1.3.2
STRATEGIC CHOICES
15.1.1.3.3
WEAKNESS/COMPETITIVE THREATS
15.1.2
ABBOTT
15.1.3
MASIMO
15.1.4
APPLE INC.
15.1.5
DEXCOM, INC.
15.1.6
MEDTRONIC
15.1.7
IRHYTHM TECHNOLOGIES, INC.
15.1.8
BIOINTELLISENSE, INC.
15.1.9
F. HOFFMANN-LA ROCHE LTD
15.1.10
KONINKLIJKE PHILIPS N.V.
15.1.11
GE HEALTHCARE
15.1.12
BIOBEAT
15.1.13
EMPATICA INC.
15.1.14
VITALCONNECT
15.1.15
AMETRIS, LLC
15.1.16
ALIVECOR, INC.
15.1.17
BOSTON SCIENTIFIC CORPORATION
15.1.18
WITHINGS
15.1.19
VIVALNK, INC
15.1.20
MEDIBIOSENSE
15.2
OTHER PLAYERS
15.2.1
SIBEL HEALTH, INC.
15.2.2
BYTEFLIES
15.2.3
STRADOS LABS
15.2.4
ONERA TECHNOLOGIES B.V.
15.2.5
EPICORE BIOSYSTEMS, INC.
16
RESEARCH METHODOLOGY
16.1
RESEARCH DATA
16.1.1
SECONDARY DATA
16.1.1.1
KEY DATA FROM SECONDARY SOURCES
16.1.2
PRIMARY DATA
16.1.2.1
KEY DATA FROM PRIMARY SOURCES
16.1.2.2
KEY PRIMARY PARTICIPANTS
16.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
16.1.2.4
KEY INDUSTRY INSIGHTS
16.2
MARKET SIZE ESTIMATION
16.2.1
BOTTOM-UP APPROACH
16.2.2
TOP-DOWN APPROACH
16.2.3
BASE NUMBER CALCULATION
16.3
MARKET FORECAST APPROACH
16.3.1
SUPPLY SIDE
16.3.2
DEMAND SIDE
16.4
DATA TRIANGULATION
16.5
FACTOR ANALYSIS
16.6
RESEARCH ASSUMPTIONS
16.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
17
APPENDIX
17.1
DISCUSSION GUIDE
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3
CUSTOMIZATION OPTIONS
17.4
RELATED REPORTS
17.5
AUTHOR DETAILS
18
CUSTOM SCOPE
18.1
WEARABLES IN BIOTECH AND PHARMA MARKET, FOR ONCOLOGY, BY THERAPY TYPE
17.2.1
IMMUNO-ONCOLOGY
17.1.2.1
CAR-T / CELL THERAPY
17.1.2.2
OTHERS
17.2.2
OTHER THERAPIES
Methodology
This study involved five major activities to estimate the current size of the wearables in pharma & biotech market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to to identify and collect information for the study of the wearables in pharma & biotech market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global wearables in pharma & biotech market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and supply side (such as C-level and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
Note: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the wearables in pharma & biotech market. These methods were also used extensively to estimate the size of various subsegments in the market.
The research methodology used to estimate the market size includes the following:
Wearables in Pharma & Biotech Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the overall market size using the market size estimation processes, the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the wearables in pharma & biotech market.
Market Definition
The wearables in pharma & biotech market comprise sensor-based, body-worn, or minimally invasive devices and associated digital platforms used to capture continuous physiological and behavioral data across the drug development and healthcare continuum. This includes products such as smartwatches, fitness bands, smart rings, continuous glucose monitors (CGMs), wearable patches, and wearable injectors, which enable real-time monitoring of parameters like heart rate, glucose levels, activity, and treatment adherence. These technologies are applied across a wide range of therapeutic areas, including cardiovascular diseases, oncology (solid tumors and hematologic malignancies), diabetes, mental health, respiratory, neurological, musculoskeletal, and women’s health conditions. The market spans key applications, such as drug discovery, clinical trials (Phase II–IV), medication adherence, chronic disease monitoring, and personalized digital therapeutics, supporting decentralized trials and real-world evidence generation. End users primarily include pharmaceutical and biotechnology companies, healthcare providers, and research organizations, all leveraging wearable technologies to enable data-driven, patient-centric care and more efficient drug development.
Key Stakeholders
- Wearable device & biosensor manufacturers (smartwatches, CGMs, patches, smart rings, wearable injectors)
- Digital health & software platform providers (mobile apps, cloud platforms, AI analytics)
- Component, sensor, & semiconductor technology providers
- Pharmaceutical companies
- Biotechnology companies
- Contract research organizations (CROs)
- Clinical trial sponsors & site management organizations
- Healthcare providers (hospitals, clinics, remote patient monitoring programs)
- Patients & caregivers
- Payers & insurers
- Regulatory & public health authorities (e.g., US Food and Drug Administration, European Medicines Agency)
- Academic institutions & research organizations
- Data management, interoperability & cloud infrastructure providers
- Cybersecurity & data privacy solution providers
- System integrators & IT service providers
- Venture capital & private equity firms
- Investors & financial institutions
- Consulting, regulatory, & compliance service providers
Report Objectives
- To define, describe, and forecast the wearables in pharma & biotech market based on product, therapeutic area, application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To strategically analyze the market structure profile of the key players and comprehensively analyze their core competencies
- To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To track and analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approvals, and alliances in the market
Customization Options:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of each company.
Geographic Analysis
- Further breakdown of the Latin America, Europe, and the Middle East & Africa markets into specific countries
⚡ Growth Signals
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Wearables in Pharma & Biotech Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Still Researching the
Wearables in Pharma & Biotech Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
Explore Wearables in Pharma & Biotech Intelligence
Powered by 17 years of MarketsandMarkets intelligence
